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Objective: We studied the prevalence of asthma and allergy in non-elite marathon
runners and investigated the effects of probiotic supplementation on allergic inflammatory
markers.
Methods: Asthma and allergies were surveyed by questionnaire, and blood eosinophils,
serum eosinophil cationic protein (ECP), total IgE, and Phadiatops were measured in 141
Finnish marathon runners who took part in the Helsinki City Marathon. They were also
randomized to receive either Lactobacillus GG (LGG) or placebo during the 3 months of the
pollen season prior to the marathon.
Results: Lifetime prevalence of physician-diagnosed asthma was 4.3% (six out of 139
athletes), of allergic rhinitis 17.3% (24/139), of food allergy 5.0% (7/139), and of atopic
eczema 4.3% (6/139). Prevalence of atopy was 31% (35/112), and 21% (24/112) of the
athletes were sensitized to birch pollen. Asthma or allergy medication was used by 20%
(28/139) of the athletes. During pollen season, serum ECP increased significantly in all
athletes, and total IgE and Phadiatops in atopics. The marathon induced a significant
eosinopenia but had no effect on serum ECP or total IgE. No differences in changes were
seen between groups receiving LGG or placebo.Elsevier Ltd. All rights reserved.
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Figur
A. Moreira et al.1124Conclusion: Non-elite marathon runners have asthma and allergies similar to Finnish
general population. LGG supplementation did not prevent the increase of allergic markers
during the pollen season, or the eosinopenia induced by the marathon.
& 2006 Elsevier Ltd. All rights reserved.Background
Evidence suggests an increased risk of asthma and bronchial
hyperresponsiveness in elite athletes.1–3 Plausible biological
explanations include type of sports, training environment
and athlete’s atopic background.4–6
Strenuous exercise, such as a marathon run, can lead to a
temporary immunosuppression, with impairment of bothe 1 Flow diagram of subjectsinnate and acquired immune responses.7 Several nutritional
countermeasures to this immunosuppression have been tried
without success.8 Probiotic lactic acid bacteria can be
defined as ‘‘a live microbial food ingredient that is beneficial
to health’’.9 In addition to the effects on non-immunologic
gut defence these bacteria promote both innate and
acquired immune responses, and their protective role in
allergy development has also been recently suggested.10,11through each stage of the study.
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Allergy and probiotics in marathon runners 1125We studied the prevalence of atopic sensitization and
related clinical conditions in marathon runners and investi-
gated the effects of probiotic supplementation during pollen
season and during the marathon.Methods
Participants
Marathon runners planning to attend the 2003 Helsinki City
Marathon (HCM) were recruited through an invitation letter
sent to the former HCM participants and a call on a national
runner’s magazine. Runners were included if their personal
best marathon time for women was less than 3 h 40min and
for men less than 3 h 30min. Exclusion criteria included use
of antibiotics 2 months prior to the study, pregnancy,
lactation, gastrointestinal diseases and medication for them
and acute gastrointestinal disorders 2 months prior to the
study. All provided informed consent and the study wasTable 1 Baseline characteristics of the 139 marathon runners.
Placebo
Demographic
Age (years) 40 (10)
Sex (female:male) 8:61
Running distance last month (km) 42 (24)
Training experience (years) 7 (7)
Marathon personal best time (min) 190 (21
Total marathons completed, n 11 (14)
Diagnosis
Asthma: n (%) 3 (4.3)
Allergic rhinitis: n (%) 7 (10.1
Allergic conjunctivitis: n (%) 1 (1.4)
Food allergy: n (%) 5 (7.2)
Atopic eczema: n (%) 4 (5.8)
Any allergy: n (%) 14 (20.
Medication
Inhaled b2-agonists: n (%) 1 (1.4)
Inhaled corticosteroids: n (%) 2 (2.9)
Anti-histamines: n (%) 7 (10.1
Nasal corticosteroids: n (%) 4 (5.8)
Allergen specific IgE
Positive Phadiatops: n/total 15/55
Specific IgE to:
Betula verrucosa: n (%) 10 (18.
Phleum pratensis: n (%) 6 (10.9
Dog: n (%) 8 (14.5
Cat: n (%) 7 (12.7
Artemisia vulgaris: n (%) 5 (9.1)
Dermatophagoides pteronyssinus: n (%) 3 (5.5)
Horse: n (%) 3 (5.5)
Cladosporium herbarum: n (%) 2 (3.6)
Data are presented as mean (SD) unless otherwise indicated. No signapproved by the Ethics Committee of Hospital District of
Helsinki and Uusimaa.
Athletes answered to a structured questionnaire that
included specific allergy and asthma questions. Athletes
were considered to suffer from asthma, rhinitis, conjuncti-
vitis, atopic dermatitis or food allergy, if the diagnosis had
been made by a physician. Atopy was defined by specific IgE
to any of the allergens tested (see below).Intervention
The study was a randomized, double-blind, placebo-con-
trolled trial, which took place between April and August
2003. After a 4-week run-in period, subjects were allocated
according to computer-generated block randomization, to
receive either Lactobacillus rhamnosus GG (LGG)
(ATCC53103) or placebo containing milk-based fruit drink
supplied by Valio Ltd., Helsinki, Finland. LGG drink
contained LGG 3.0 10E8 cfu/ml. Subjects were asked to
drink two 65ml bottles of LGG or placebo drink per day. Then ¼ 69 Lactobacillus GG n ¼ 70 Total n ¼ 139
39 (9) 39 (9)
8:62 16:123
47 (38) 44 (32)
7 (6) 7 (6)
) 188 (19) 189 (20)
12 (13) 12 (14)
3 (4.3) 6 (4.3)
) 17 (24.3) 24 (17.3)
3 (4.3) 4 (2.9)
2 (2.9) 7 (5.0)
2 (2.9) 6 (4.3)
3) 23 (32.9) 37 (26.6)
3 (4.3) 4 (2.9)
2 (2.9) 4 (2.9)
) 15 (21.4) 22 (15.8)
1 (1.4) 5 (3.6)
20/57 35/112
2) 14 (24.6) 24 (21.4)
) 9 (15.8) 15 (13.4)
) 7 (12.3) 15 (13.4)
) 6 (10.5) 13 (11.6)
5 (8.8) 10 (8.9)
2 (3.5) 5 (4.5)
2 (3.5) 5 (4.5)
1 (1.2) 3 (2.7)
ificant differences between groups were found.
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A. Moreira et al.1126subject was given a possibility to use LGG (5.0 10E9 cfu/
capsule) or placebo capsules (two per day) in specific
occasions, for example during trips abroad. The needed
amount of capsules were asked and given by the study
coordinator. Twenty-seven subjects in the LGG group (3–49
days) and 28 subjects in the placebo group (3–36 days) used
the capsules. The intervention continued for 3 months until
the 2003 HCM. Compliance with the intervention was
assessed by questionnaire. During the intervention, athletes
were instructed to restrain intake of food containing
probiotics. The 2003 HCM was held on the 2nd of August at
sea level.re
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¼Outcome measurements
Blood samples were collected at (1) baseline (Train 1) 3
months before the marathon, (2) 1 week prior to the
marathon (Train 2), (3) just before the marathon (Run 1),
and (4) after completing the marathon (Run 2). Blood
samples at Train 1 and Train 2 were collected after an
overnight fasting, and Run 1 and Run 2 collected in the
Olympic Stadium and immediately transported to the
laboratory. Eosinophil cationic protein (ECP), serum total
IgE levels, and Phadiatops test were determined by
Pharmacia CAP system (Pharmacia Diagnostics, Uppsala,
Sweden) according to manufacturers instructions. When
Phadiatops was positive, quantitative IgE antibodies against
Phleum pratensis, Betula verrucosa, Artemisia vulgaris,
Cladosporium herbarum, Dermatophagoides pteronyssinus,
and horse, cat and dog dander were determined. Measuring
range was 2–200 mg/L for serum ECP, and 0.35–100 kUA/l for
serum Phadiatops and specific IgE.Ta
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e.Statistical analysis
All analyses were conducted using the ‘‘intention-to-treat’’
approach, including all randomized athletes who took at
least one dose of the study preparation and who had at least
one postbaseline efficacy variable measurement. The ITT
analyses were used for all efficacy measures. Missing data
for those who withdrew from the study before its comple-
tion or from whom data was missing for reasons unrelated to
treatment were estimated using an expectation-maximiza-
tion algorithm. Overall, data was imputed in 5.9% (70/1182)
of the samples (60/644 for the training period and 10/538
for the marathon). Because of their skewed distributions, all
comparisons were made after logarithmic transformation.
To permit analysis in the log scale, a constant (0.1) was
added to each value of the percent eosinophil count to
eliminate 0 values. Baseline characteristics were compared
using Fisher exact test for categorical variables or Student’s
test for numeric variables; changes within groups were
compared using paired t-test and differences between
placebo and LGG groups were compared by analysis of
covariance (ANCOVA) with baseline value (Train 1 or Run 1)
as covariate. Values of po0:05 were regarded as significant.
No adjustment was made for multiple testing, but this
information can be obtained by multiplying the actual p
value by the number of comparisons made.
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Allergy and probiotics in marathon runners 1127Results
Of the 144 volunteers recruited to the study, 141 fulfilled
the entry criteria and were randomized. Two subjects
withdrew before starting the intervention and were ex-
cluded from the analysis (Fig. 1).Prevalence of asthma and allergy
Physician-diagnosed asthma was reported by 6 (4.3%) and
allergic rhinitis by 24 (17.3%) athletes (Table 1).
Five of the six athletes with asthma, and 13 of the 24
athletes (62%) with rhinitis were atopic according to the
Phadiatops result. Twenty-eight athletes (20%) reported
current use of asthma or allergy medication. Eight athletes,
however, did not provide medical diagnosis justifying the
medication use.
Phadiatops was positive in 35 of the 112 athletes tested
(31%); 21.4% were sensitized to birch pollen, 13.4% to
timothy pollen, 13.4% to dog and 11.6% to cat. Nineteen of
the sensitized runners (54%) did not, however, report any
symptoms. Phadiatops-positive athletes (defined here as
atopics) had higher serum total IgE compared with Phadia-
tops-negative athletes (geometric mean, 112 vs. 32 kUA/L;
po0:001), but blood eosinophils numbers or serum ECP
values were not different. When athletes were categorized
by their running performance, no differences in atopy
prevalence were observed.0
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Figure 2 Eosinophil cationic protein (ECP, mcg/L), blood eosinoph
and after the training period (Train1 and Train2), and before and af
geometric means (95% CI).Effect of LGG during 3-month training
Training period occurred during the pollen season. In 2003,
the highest pollen counts were observed between May and
July.12 In all runners, blood eosinophil numbers did not
change, but serum ECP increased. No differences in changes
of blood eosinophil numbers, serum ECP, total IgE and
Phadiatops were observed between the LGG or placebo
groups (Table 2, Fig. 2) or between the atopic (Phadiatops-
positive) or non-atopic runners during the training period
(Table 3). In the 35 atopic runners, total serum IgE and
Phadiatops increased but blood eosinophil numbers or
serum ECP did not change.Effect of LGG during 1 week prior to and during
marathon run
In all runners, the number of blood eosinophils and serum
ECP levels decreased significantly during the week preced-
ing the run. In atopic runners, total IgE increased signifi-
cantly. No differences in changes were observed between
the LGG or placebo groups during 1 week before the run
(Table 4).
In all runners, the marathon run induced a significant
eosinopenia, but serum ECP did not change. In atopic
runners, similar eosinopenia was observed as in the whole
group. The marathon run did not affect total IgE of the
atopic runners. The responses to the marathon run were
similar in the LGG and placebo groups (Table 5, Fig. 2).0
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Table 3 Changes of blood eosinophils, ECP and total IgE for atopic (positive Phadiatop) vs. non atopic athletes before (Train 1) and after (Train 2) the 3 month training
period.
Atopic athletes Non-atopic athletes
n Train 1 Train 2 Change n Train 1 Train 2 Change p-valuey
B-Eos (%) 35 3.9 (2.5) 4.0 (2.3) 0.2 (0.4,0.7) 77 3.7 (2.4) 3.6 (2.1) 0.1 (0.5,0.3) 0.57
ECP (mcg/L) 35 8.6 (6.5) 10.7 (8.7) 2.0 (0.3,4.3) 77 7.3 (5.6) 10.8 (7.1) 3.5 (2.0,5.0);
po0.001
0.16
Total IgE (kUA/L) 35 190 (32) 217 (225) 27 (12,43);
p ¼ 0.0050
77 53 (53) 53 (49) 0 (3,4) 0.15
Values are shown as mean (SD) or mean differences (IC 95%) were appropriate.
ECP: eosinophil cationic protein; B-Eos: blood eosinophils.
Paired samples t-test.
yAnalysis of covariance, baseline value as covariate.
Table 4 Changes of blood eosinophils, serum ECP, and total IgE a week before (Train 2) and just before (Run 1) the Helsinki City Marathon in athletes supplemented with
Lactobacillus GG or placebo.
Placebo Lactobacillus GG Total Placebo vs.
Lactobacillus
GG
n Train 2 Run 1 Change n Train 2 Run 1 Change n Train 2 Run 1 Change p-valuey
B-Eos (%) 56 3.8 (2.3) 2.9 (2.0) 1.0 (1.3,0.7);
po0.001
61 3.6 (2.2) 2.9 (2.3) 0.7 (1.2,0.3);
po0.001
117 3.7 (2.3) 2.9 (2.1) 0.9 (1.1,0.6);
po0.001
0.50
ECP (mcg/L) 56 10.0 (6.6) 9.6 (5.9) 0.4 (2.1,1.3) 61 12.0 (8.4) 8.9 (6.4) 3.1 (5.4,0.9);
p ¼ 0.010
117 11.1 (7.6) 9.2 (6.1) 1.8 (3.3,0.4);
p ¼ 0.043
0.069
Total IgE
(kUA/L)
15 243 (181) 260 (201) 16 (3,29); p ¼ 0.017 20 198 (255) 203 (269) 5 (6,16) 35 218 (225) 227 (240) 10 (2,18);
p ¼ 0.0030
0.10
Values are shown as mean (SD) or mean differences (IC 95%) were appropriate.ECP: eosinophil cationic protein; B-Eos: blood eosinophils.
Paired samples t-test.
yAnalysis of covariance, Train 2 value as covariate.
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Allergy and probiotics in marathon runners 1129Discussion
Asthma is diagnosed more frequently in elite athletes than
in the general population.4,13–16 Atopy and type of sports
appear to be the two major risk factors; atopic long distance
runners had a 42-fold increased risk of asthma compared to
non-atopic non-athletes.17 We observed a 4.3% prevalence
of physician-diagnosed asthma in non-elite athletes. This is
close to asthma prevalence in the Finnish general population
(between 5.5% and 6.6%).18,19 Of the runners, 88% were
male, and asthma prevalence of 5.1% of Finnish males has
been reported.18 In a sample of 71 Finnish long distance
runners, 7.0% had asthma.17 Of 108 endurance athletes
supported by the Finnish National Olympic Committee, and
of 103 athletes from Finnish national teams, 22.2%20 and
16%, respectively, had asthma.13 The increased figures of
asthma prevalence in high level competitive athletes have
been attributed to an irritant-induced airway inflammation
and bronchial hyperreactivity,2,6,21 which have attenuated
after discontinuing training and competition.2 The relatively
low prevalence of asthma in our athletes may reflect a
‘‘healthy runner effect’’. Our subjects were non-elite
runners, and individuals having symptoms suggestive of
asthma do not easily continue long-distance running; they may
change their hobby to other types of sports. The prevalence of
allergic rhinitis in athletes, assessed by the questionnaire has
varied from 16.8% to 41%4,14,15,22–26 while the prevalence of
allergic rhinitis in Finnish population ranges from 26% to 36%.18
The prevalence of allergic rhinitis (17.3%) in the present study
is close to the figures of the general population. In contrast,
the prevalence of allergic conjunctivitis (2.9%) was low,
although similar to another study (3.6%) of athletes.26 Athletes
conjunctivas are not exposed to such an increased amount of
airborne allergens than airway mucosa due to a high
ventilation rate. The overall prevalence of atopy (31%) was
similar to the figure previously reported in Finnish long-
distance runners (33.8%).17 Sensitization rates to birch,
timothy, mugwort, D. pteronyssinus and C. herbarum were
almost coincident with those reported for Helsinki adult
population,27 not suggesting an increased risk of sensitization
in non-elite runners. In Finland, between 1994 and 2000, the
use of asthma medication increased 42% to a figure near 5% of
the general population.28 However, the use of asthma
medication has been four times more frequent (22%) in Finnish
elite long-distance runners.17 In the present study, the
frequency of reported asthma medication (2.9%) was close to
figures in the general population.
During the training period, the main pollen season in
Finland, we observed: (1) an increase of serum ECP in all
athletes, and of total IgE and Phadiatops in the atopics, and
(2) LGG intake had no effect on this variation neither in
atopic nor in non-atopic athletes.
Higher levels of ECP during the birch pollen season in
healthy subjects have been reported but remain unex-
plained.29 Exposure to pollen proteases in vitro causes
concentration-dependent detachment of airway epithelial
cells.30 Disruption of the epithelial barrier by proteases in
pollens might thus occur in some subjects when training
outdoor, with high ventilation rates during the pollen
season, contributing to a low-grade systemic inflammation.
Although probiotic supplementation may have a role in
prevention and management of allergic eczema,10,11,31 only
ARTICLE IN PRESS
A. Moreira et al.1130a few trials have addressed its effects on IgE responses in
established allergic sensitization. In animal models, the
administration of Lactobacillus plantarum L-137 to mice fed
with a casein diet suppressed the elevation of casein-
specific IgE levels by an anti-casein IgG1mechanism.32 In a
food allergy model, the intraperitoneal injection of Lacto-
bacillus casei strain Shirota to OVA-TCR-Tg mice-induced
suppression of IgE, IgG1 and systemic allergic reactions.33 L.
casei induced IFN-gamma, but inhibited IL-4 and IL-5
secretion, and markedly suppressed total and antigen-
specific IgE secretion by OVA-stimulated splenocytes ob-
tained from OVA-primed BALB/c mice.34 Probiotics may
regulate IL-4 and IL-5 expression35 and affect eosinophil
development and activation. In human studies, a trend to
decrease blood eosinophils was noticed after L. acidophilus
supplementation to asthma patients.36,37 Our findings do not
support probiotic supplementation during pollen season in
reducing the seasonal increase of IgE response in runners,
but do not rule out possible beneficial effects of probiotics
in other type of sports, e.g. in cold air sports or swimming.
Pre-competitive stress and stop of heavy training during
the week preceding the marathon could play a major role in
the decrease of ECP and blood eosinophils. Acute exercise
has increased numbers of neutrophils and monocytes and
decreased lymphocytes in cell counts.7 Changes in eosino-
phils after marathon or strenuous exercise have been
reported with conflicting results. Nieman et al.38 reported
eosinopenia in 10 marathoners after a 3 h run in a laboratory
setting; the eosinopenia was maintained for at least 21 h. In
another study, cell counts and ECP from seven athletes
swimming 5-km were unaffected.39 Increase in serum
cortisol levels seen after a marathon may have a role in
the observed marathon-induced eosinopenia.7 LGG did not
prevent the eosinopenia.
We conclude that in non-elite long-distance runners,
prevalence of allergic diseases is similar to the general
population. LGG did not affect the allergic markers during
the training period or the marathon race.Acknowledgments
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